Last updated: August 31, 2026
Bayer Intellectual Property GmbH sued Taro Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware after Taro filed an abbreviated new drug application seeking approval for generic rivaroxaban tablets, the active ingredient in Xarelto. The case, No. 1:17-cv-00462, was a Hatch-Waxman patent-infringement action based on Taro’s Paragraph IV certifications. The dispute was resolved without a publicly reported trial judgment; the settlement terms were not disclosed in the public docket.
What drug and ANDA were at issue in Bayer v. Taro?
The case concerned rivaroxaban tablets in strengths corresponding to Bayer and Janssen’s Xarelto product.
| Item |
Information |
| Branded drug |
Xarelto |
| Active ingredient |
Rivaroxaban |
| Dosage form |
Oral tablets |
| Plaintiff |
Bayer Intellectual Property GmbH |
| Defendant |
Taro Pharmaceutical Industries Ltd. |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:17-cv-00462 |
| Legal basis |
Hatch-Waxman patent litigation |
| Regulatory trigger |
Taro ANDA filing with Paragraph IV certifications |
| Commercial objective |
FDA approval and generic entry for rivaroxaban tablets |
Xarelto is an oral factor Xa inhibitor approved for several indications, including prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prevention of deep-vein thrombosis and pulmonary embolism, and prevention of venous thromboembolism after certain orthopedic surgeries (U.S. Food and Drug Administration [FDA], 2023).
Taro’s ANDA filing represented a direct challenge to Bayer’s listed patents. Under the Hatch-Waxman framework, the Paragraph IV certifications created an artificial act of infringement and allowed Bayer to sue before commercial generic launch.
What patents did Bayer assert against Taro?
Public case materials identify the Xarelto patent family as including compound, composition, and method-of-use rights. The patents most closely associated with the 2017 rivaroxaban ANDA litigation included the following:
| Patent |
General subject matter |
Relevance to Xarelto litigation |
| U.S. Patent No. 7,157,456 |
Rivaroxaban compound and related oxazolidinone chemistry |
Core active-ingredient protection |
| U.S. Patent No. 8,822,438 |
Rivaroxaban pharmaceutical use and treatment claims |
Method-of-use protection |
| U.S. Patent No. 9,340,614 |
Rivaroxaban treatment claims and related therapeutic use |
Later-expiring use protection |
The exact claims and patents in a particular ANDA case must be read from the complaint, infringement contentions, and claim-construction record. Hatch-Waxman complaints frequently identify every Orange Book-listed patent challenged by the ANDA, while subsequent proceedings narrow the claims at issue.
The '456 patent was the foundational compound patent for rivaroxaban. The later patents were important because they could extend protection beyond the basic compound patent through treatment methods or pharmaceutical-use claims. Such later patents can delay generic approval or constrain the indications for which a generic applicant can launch.
When did Bayer file the lawsuit against Taro?
Bayer filed the action in 2017 in the District of Delaware. The docket number is 1:17-cv-00462. The suit followed Taro’s ANDA filing and Paragraph IV notice to the patent holder.
The case was one of several coordinated or parallel Xarelto cases filed against generic-drug companies. Related defendants in the broader litigation included major generic manufacturers that challenged the same or overlapping rivaroxaban patents.
The 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii) was a central regulatory consequence of the filing. Unless shortened or otherwise affected by court action, the stay generally prevents FDA approval of the challenged ANDA for 30 months after the patent owner receives Paragraph IV notice.
What was the legal theory in Bayer v. Taro?
Bayer’s claim was that Taro’s proposed generic rivaroxaban product would infringe one or more listed patents under 35 U.S.C. § 271(e)(2). The asserted theories likely tracked the ANDA certifications and the proposed product’s labeling.
The principal issues in this type of action are:
- Whether the ANDA product falls within the asserted composition or product claims.
- Whether Taro’s proposed labeling induces infringement of method-of-use claims.
- Whether the asserted claims are valid over prior art.
- Whether the claims are enforceable.
- Whether Taro’s Paragraph IV invalidity and noninfringement positions would support an earlier launch.
For rivaroxaban, the distinction between product claims and method-of-use claims was commercially important. A generic company may be able to obtain approval through a label that omits a patented indication, but a skinny-label strategy does not eliminate all infringement exposure. Product composition claims can block approval or sale across indications, while method-of-use patents are more dependent on labeling, promotion, prescribing behavior, and the scope of the asserted claims.
What was the outcome of the Taro litigation?
The case did not produce a publicly reported final trial judgment establishing that Taro infringed or that the asserted patents were invalid. Public docket information indicates that the action concluded through a settlement-related dismissal rather than a merits verdict.
The material commercial terms of the settlement were not publicly disclosed. The record does not establish a publicly announced Taro launch date, royalty structure, authorized-generic arrangement, or license scope.
This distinction matters. A dismissal following settlement does not resolve the validity of the asserted patents for other generic defendants. It also does not necessarily establish whether Taro obtained a license, agreed to a negotiated entry date, or abandoned its ANDA challenge. Those terms are commonly contained in confidential settlement agreements and may be summarized only in a Federal Trade Commission filing or a redacted court submission.
Did Bayer win a patent judgment against Taro?
No publicly reported merits judgment against Taro should be treated as the outcome of this docket. The case ended without a reported trial verdict or appellate decision specifically determining Taro’s infringement or invalidity defenses.
The case therefore has limited precedential value. Its principal significance is commercial and procedural:
- It triggered Hatch-Waxman litigation over Taro’s ANDA.
- It placed Taro’s generic launch at risk during the 30-month stay.
- It formed part of the broader Xarelto patent-dispute program.
- It ended without a public ruling that could independently invalidate or uphold the asserted patents.
What was the Orange Book status of Xarelto?
The FDA Orange Book listed patents associated with Xarelto and rivaroxaban products. The listed patents covered different aspects of the product, including the active ingredient and therapeutic uses. Orange Book listings are relevant to ANDA applicants because they determine which certifications must be made and which listings can trigger a Paragraph IV action.
| Protection category |
Commercial effect |
| Compound patent |
Can block generic rivaroxaban broadly until expiration or license |
| Formulation or composition patent |
Can restrict the specific dosage form or formulation |
| Method-of-use patent |
Can affect approval or labeling for a protected indication |
| Pediatric exclusivity |
Can add six months to qualifying patent protection |
| Regulatory exclusivity |
May operate independently of patent expiry |
Orange Book listing does not itself prove that a patent is valid or infringed. It identifies patents that the NDA holder or patent owner has submitted for listing. Generic applicants can challenge those patents through Paragraph IV certifications, litigation, or settlement.
What formulations were protected by the Xarelto patent estate?
The Xarelto estate included protection relevant to oral rivaroxaban tablet products. Formulation-related rights can address:
- The amount of rivaroxaban in the tablet.
- Excipients and pharmaceutical composition.
- Dissolution or bioavailability characteristics.
- Solid dosage-form structure.
- Administration with or without food.
- Use in patient populations covered by approved labeling.
Rivaroxaban presents a formulation challenge because exposure can vary by dose and administration conditions. The 15-mg and 20-mg products have food-related administration requirements, while the 2.5-mg and 10-mg strengths have different labeling instructions. A generic applicant must demonstrate bioequivalence for each proposed strength and comply with the approved labeling framework.
The formulation and labeling distinctions affect both patent risk and launch strategy. A company that avoids a method-of-use claim may still face product-level claims if the generic tablet falls within a composition patent.
How strong was Bayer’s patent estate?
Bayer’s estate had meaningful blocking power because it combined several protection types rather than relying only on the original compound patent.
Strengths
The compound patent provided the broadest commercial protection. Later treatment patents could extend the period during which generic applicants faced litigation risk. Multiple listed patents also increased the cost and complexity of Paragraph IV challenges.
Bayer and Janssen had substantial regulatory, clinical, and commercial evidence supporting the approved uses of rivaroxaban. That evidence can support inducement theories when generic labeling tracks protected indications.
Weaknesses
Method-of-use claims are narrower than compound claims and can be attacked through label carve-outs, noninfringement arguments, and prior-art defenses. Later-filed patents also face greater vulnerability to obviousness challenges, particularly where the asserted treatment reflects known use of a known anticoagulant.
A settlement rather than a merits judgment leaves the public record without a definitive determination of how the asserted patents would have performed against Taro’s specific ANDA.
What generic entry risks did Taro face?
Taro faced four principal risks:
- Regulatory delay. The Paragraph IV suit triggered the statutory 30-month stay.
- Injunction or delayed entry. Bayer could seek an order preventing commercial launch until patent expiry.
- Damages exposure. If Taro launched at risk and Bayer prevailed, Taro could face damages and enhanced litigation costs.
- Label restrictions. A launch limited by a Section viii statement or skinny label could reduce the commercial value of the ANDA.
Taro also faced the risk that an unfavorable ruling in related Xarelto litigation would affect its negotiating position, even if the Taro docket itself did not reach judgment.
Which companies were challenging Xarelto patents?
The 2017 Xarelto litigation involved multiple generic-drug companies, including Taro and other ANDA applicants. These cases were commercially linked because they concerned the same branded product and overlapping patent rights, but each defendant’s outcome depended on its own ANDA, formulation, proposed labeling, defenses, and settlement terms.
Parallel litigation can produce different entry dates. The first generic settlement may receive commercial preference, while later applicants may accept later entry dates or other restrictions. A settlement with one defendant does not automatically authorize all other generic manufacturers to launch.
Did the case affect biosimilar risk?
No. Rivaroxaban is a chemically synthesized small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.
The principal competitors were generic manufacturers seeking approval under the Hatch-Waxman Act. Biosimilar concepts such as interchangeable designation, reference-product exclusivity, and the Biologics Price Competition and Innovation Act were not applicable to this dispute.
What was the commercial exposure for Xarelto?
Xarelto was a major anticoagulant franchise for Bayer and Janssen. In 2023, Bayer reported approximately €4.7 billion in Xarelto sales, although the product economics were shared across the Bayer and Johnson & Johnson commercial relationship (Bayer AG, 2024).
Generic entry would affect:
- Net price and gross-to-net discounts.
- Prescriber and payer substitution.
- Volume retention in atrial fibrillation and venous-thromboembolism markets.
- Contracting leverage with pharmacy benefit managers.
- Revenue allocation between Bayer and Janssen.
- The value of later-life-cycle indications and formulations.
The Taro settlement could not be quantified from the public docket because its economic terms were not disclosed.
What is the current litigation significance of Bayer v. Taro?
The case is best characterized as a resolved Hatch-Waxman ANDA dispute without a public merits decision. It is relevant to Xarelto exclusivity analysis because it shows how Bayer used overlapping compound, formulation, and method-of-use patents to manage generic challenges.
It should not be cited as a holding that the Xarelto patents were valid, infringed, or enforceable against Taro. Those questions require analysis of the specific judgments and appeals in the related Xarelto cases that proceeded further.
Key Takeaways
- Bayer sued Taro in Delaware over a Paragraph IV challenge involving generic rivaroxaban tablets.
- The branded reference product was Xarelto.
- The relevant patent estate included compound, pharmaceutical-composition, and method-of-use protection.
- The case ended through settlement-related dismissal without a publicly reported merits judgment.
- Settlement terms, including any Taro launch date or license rights, were not publicly disclosed.
- The dispute involved generic risk, not biosimilar risk.
- The case had commercial significance because Xarelto generated multibillion-euro annual sales for Bayer and its commercial partner.
- The docket should not be treated as precedent on the validity or infringement of the asserted patents.
FAQs About Bayer v. Taro and Xarelto Patent Litigation
Was Taro authorized to launch generic rivaroxaban after the settlement?
The public docket does not disclose sufficient settlement terms to establish whether Taro received a license, an authorized-generic right, or a specific launch date.
Did Bayer assert the original rivaroxaban compound patent?
The Xarelto litigation program included the original compound patent family, including U.S. Patent No. 7,157,456. The precise patent set applicable to Taro must be determined from the filed complaint and docket submissions.
Is Bayer v. Taro still pending?
The action was resolved through a settlement-related dismissal and is not a pending merits dispute in the ordinary sense.
Does the Taro settlement establish Xarelto patent validity?
No. A private settlement does not create a judicial finding that the patents are valid or infringed.
Can a generic company launch rivaroxaban with a skinny label?
A skinny-label launch may reduce method-of-use infringement exposure, but it cannot avoid valid product or composition claims. The answer depends on the patent claims, proposed labeling, product formulation, and applicable FDA approval conditions.
References
Bayer AG. (2024). Annual report 2023. https://www.bayer.com/en/investors/annual-reports
CourtListener. (n.d.). Bayer Intellectual Property GmbH v. Taro Pharmaceutical Industries Ltd., No. 1:17-cv-00462, U.S. District Court for the District of Delaware. https://www.courtlistener.com/
U.S. Food and Drug Administration. (2023). Xarelto prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent Nos. 7,157,456, 8,822,438, and 9,340,614. https://patentcenter.uspto.gov/
